Fig. 5

LY3300054 demonstrates anti-tumor efficacy in xenograft tumor models reconstituted with human immune cells. Antibody treatment (indicated by red arrows), either human IgG or LY3300054, was delivered by intra-peritoneal injection in each case at 10 mg/kg. Tumor growth was monitored by caliper, and results are represented as a geometric mean of tumor volumes ± SEM. Panel a: Co-implantation model: NCI-H292 tumor cells and freshly isolated human PBMC were co-implanted subcutaneously into the flanks of NSG mice. n = 8 for all groups. Panel b: Established tumor model: HCC827 tumor cells were implanted subcutaneously into the flanks of NSG mice. When tumors reached volumes of ~ 300 mm³ (approximately 5 weeks), mice were infused with previously expanded human T cells (black arrow). n = 8 for all groups. Panels c and d: Established tumor models in CD34+ hHSC-reconstituted animals: HCC827 tumors (NSG, panel |C) or OV79 tumors (NOG, panel D). Mice were implanted subcutaneously with either HCC827 or OV79 tumor fragments at ~ 15–17 weeks of age (~ 13–15 weeks post HSC engraftment). HCC827 tumors were allowed to grow to ~ 200 mm³ (4 weeks) and OV79 were allowed to grow to ~ 150 mm³ (18 days) before starting weekly treatments of either human IgG1 or LY3300054 at 10 mg/kg. n = 5–9 per group. Statistically significant difference is indicated* (two-way repeated measurement ANOVA, RM-ANOVA)